179.00 -1.98 (-1.09%)
Pre-Market: 8:31AM EDT
|Bid||164.40 x 800|
|Ask||0.00 x 1800|
|Day's Range||177.27 - 182.18|
|52 Week Range||123.00 - 197.86|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||53.54|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||191.60|
Stock futures were steady amid a wave of earnings from Snap, Texas Instruments, eBay, iRobot and more. Texas Instruments signaled that a chip downturn may last longer than expected.
Boston Scientific earnings and sales missed Q1 estimates while Thermo Fisher earnings beat. Boston Scientific stock dipped while its fellow medical device maker edged higher.
Medical device companies Edwards Lifesciences and Stryker topped first-quarter earnings expectations late Tuesday, though Stryker sales were just in line.
On a per-share basis, the Irvine, California-based company said it had net income of $1.18. Earnings, adjusted for non-recurring costs, were $1.32 per share. The results beat Wall Street expectations. ...
IRVINE, Calif. , April 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
Edwards Lifesciences Corporation (NYSE:EW), a large-cap worth US$37b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balance sheet and high market...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
Twitter, Lockheed Martin, iRobot, Edwards Lifesciences and other top stocks report earnings on Tuesday. Here's a look at what to expect.
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
IRVINE, Calif., April 18, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the completion of its acquisition of CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring. Edwards announced in February that it had signed an agreement to acquire CASMED. Under the terms of the agreement, Edwards paid $2.45 in cash for each common share of CASMED, which equates to an equity value of approximately $100 million.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (NYSE:EW) is a top holding because we think there continues to be a multiyear runway for excellent top-line and bottom-line growth. Adjusted sales during the Company's fourth quarter grew +10%, driven by a +11% increase in transcatheter heart valve (THV) therapies. Edwards also released positive results of a highly anticipated trial that evaluated the performance of transcatheter aortic valve replacement (TAVR) in a previously unserved population.
Top first quarter performance detractors include Qualcomm, Berkshire Hathaway, Booking Holdings, Alphabet Class C, and Starbucks, plus Charles Schwab and C.H. Robinson. During the quarter we sold Qualcomm and trimmed positions in Ross Stores, Old Dominion Freight Line, and Charles Schwab.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
IRVINE, Calif. , April 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Edwards LifesciencesRead More...